| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8526279 | Biomedicine & Pharmacotherapy | 2018 | 12 Pages |
Abstract
Our results suggest that SP is not an unequivocal CSLC-marker. However, SP could play an important role in modulating HYP-treatment and serve as a negative predictive tool for HYP-based therapies. Moreover, the use of supplements containing HYP by cancer patients should be carefully considered, due to its proposed effect on drug efflux and complex impact on tumor cells, which have not yet been sufficiently characterized.
Keywords
ALDHSCIDPDDHBSSBcrpHSP90HYPPDTCDH1MDR1LRPFSCHEPESP-gpFBSMRP1FACSP-glycoprotein 1MDRRFUPBSDEABHoechst 33342H333424-(2-hydroxyethyl)-1-piperazineethanesulfonic acidATP-binding cassette transportersNAD(P)aldehyde dehydrogenaseEDTAEthylenediaminetetraacetic acidPhotodynamic diagnosisEMTABC transportersPhotodynamic therapyfluorescence-activated cell sortingNSCLCfetal bovine serumcancer stem-like cellsshoPhotosensitizerPhosphate buffered salineHank’s balanced salt solutionMultidrug resistancenicotinamide-adenine dinucleotide phosphateHypericinrelative fluorescence unitforward scatterHeat shock protein 90Lung resistance-related proteinMultidrug Resistance-associated Protein 1multidrug resistance protein 1Propidium iodidenon-small cell lung carcinomasevere combined immunodeficiencyEpithelial-mesenchymal transition
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jana Vargová, JaromÃr MikeÅ¡, Rastislav Jendželovský, Lucia MikeÅ¡ová, Barbora Kuchárová, ĽubomÃr Äulka, Radek Fedr, Ján RemÅ¡Ãk, Karel SouÄek, Alois KozubÃk, Peter FedoroÄko,